Harmony Biosciences (HRMY) Competitors $32.75 +0.51 (+1.58%) As of 07/8/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock HRMY vs. ELAN, RVMD, LEGN, GRFS, TGTX, LNTH, NUVL, TLX, AXSM, and ADMAShould you be buying Harmony Biosciences stock or one of its competitors? The main competitors of Harmony Biosciences include Elanco Animal Health (ELAN), Revolution Medicines (RVMD), Legend Biotech (LEGN), Grifols (GRFS), TG Therapeutics (TGTX), Lantheus (LNTH), Nuvalent (NUVL), Telix Pharmaceuticals (TLX), Axsome Therapeutics (AXSM), and ADMA Biologics (ADMA). These companies are all part of the "pharmaceutical products" industry. Harmony Biosciences vs. Its Competitors Elanco Animal Health Revolution Medicines Legend Biotech Grifols TG Therapeutics Lantheus Nuvalent Telix Pharmaceuticals Axsome Therapeutics ADMA Biologics Elanco Animal Health (NYSE:ELAN) and Harmony Biosciences (NASDAQ:HRMY) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, media sentiment, earnings, profitability, valuation, analyst recommendations, institutional ownership and risk. Which has better valuation and earnings, ELAN or HRMY? Elanco Animal Health has higher revenue and earnings than Harmony Biosciences. Harmony Biosciences is trading at a lower price-to-earnings ratio than Elanco Animal Health, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioElanco Animal Health$4.44B1.65$338M$0.7419.93Harmony Biosciences$714.73M2.63$145.49M$2.6212.50 Is ELAN or HRMY more profitable? Harmony Biosciences has a net margin of 20.53% compared to Elanco Animal Health's net margin of 8.43%. Harmony Biosciences' return on equity of 24.32% beat Elanco Animal Health's return on equity.Company Net Margins Return on Equity Return on Assets Elanco Animal Health8.43% 7.54% 3.57% Harmony Biosciences 20.53%24.32%15.92% Do analysts recommend ELAN or HRMY? Elanco Animal Health presently has a consensus target price of $15.33, indicating a potential upside of 3.95%. Harmony Biosciences has a consensus target price of $53.63, indicating a potential upside of 63.74%. Given Harmony Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Harmony Biosciences is more favorable than Elanco Animal Health.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Elanco Animal Health 0 Sell rating(s) 4 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.50Harmony Biosciences 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13 Do institutionals and insiders believe in ELAN or HRMY? 97.5% of Elanco Animal Health shares are owned by institutional investors. Comparatively, 86.2% of Harmony Biosciences shares are owned by institutional investors. 0.9% of Elanco Animal Health shares are owned by company insiders. Comparatively, 23.6% of Harmony Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Which has more volatility & risk, ELAN or HRMY? Elanco Animal Health has a beta of 1.67, suggesting that its stock price is 67% more volatile than the S&P 500. Comparatively, Harmony Biosciences has a beta of 0.83, suggesting that its stock price is 17% less volatile than the S&P 500. Does the media prefer ELAN or HRMY? In the previous week, Elanco Animal Health had 10 more articles in the media than Harmony Biosciences. MarketBeat recorded 10 mentions for Elanco Animal Health and 0 mentions for Harmony Biosciences. Harmony Biosciences' average media sentiment score of 1.00 beat Elanco Animal Health's score of 0.43 indicating that Harmony Biosciences is being referred to more favorably in the news media. Company Overall Sentiment Elanco Animal Health Neutral Harmony Biosciences Positive SummaryHarmony Biosciences beats Elanco Animal Health on 11 of the 17 factors compared between the two stocks. Get Harmony Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for HRMY and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding HRMY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart HRMY vs. The Competition Export to ExcelMetricHarmony BiosciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.85B$2.88B$5.47B$8.95BDividend YieldN/A2.46%5.25%4.06%P/E Ratio12.5020.8027.0020.10Price / Sales2.63286.98435.75120.29Price / Cash10.9441.1936.8257.86Price / Book2.837.487.985.56Net Income$145.49M-$55.04M$3.16B$248.40M7 Day Performance1.99%2.44%2.40%4.67%1 Month Performance-7.54%1.90%2.19%6.64%1 Year Performance-5.26%4.35%33.82%21.31% Harmony Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)HRMYHarmony Biosciences4.8248 of 5 stars$32.75+1.6%$53.63+63.7%+0.6%$1.85B$714.73M12.50200Positive NewsELANElanco Animal Health2.3486 of 5 stars$14.29flat$15.17+6.1%+5.7%$7.10B$4.44B19.319,000RVMDRevolution Medicines4.5646 of 5 stars$36.79-0.3%$67.58+83.7%-7.9%$6.85B$11.58M-9.20250Positive NewsLEGNLegend Biotech3.0504 of 5 stars$35.49+2.5%$76.20+114.7%-20.9%$6.52B$627.24M-60.152,609Positive NewsAnalyst ForecastGRFSGrifols4.0825 of 5 stars$9.04+2.0%$10.30+13.9%+7.0%$6.22B$7.81B7.7323,822News CoverageAnalyst UpgradeTGTXTG Therapeutics3.89 of 5 stars$35.99-2.0%$40.80+13.4%+82.1%$5.71B$386.39M149.96290News CoveragePositive NewsLNTHLantheus4.4152 of 5 stars$81.86+0.5%$130.50+59.4%+4.6%$5.66B$1.53B23.26700NUVLNuvalent3.7406 of 5 stars$76.30-4.2%$119.60+56.7%+8.9%$5.48BN/A-17.3840TLXTelix PharmaceuticalsN/A$16.07+0.4%$22.00+36.9%N/A$5.44B$516.72M0.00N/AAXSMAxsome Therapeutics4.7718 of 5 stars$104.39+1.0%$172.33+65.1%+29.6%$5.14B$432.16M-18.09380ADMAADMA Biologics4.1295 of 5 stars$18.21+0.3%$27.67+51.9%+53.0%$4.35B$426.45M21.42530Positive News Related Companies and Tools Related Companies Elanco Animal Health Alternatives Revolution Medicines Alternatives Legend Biotech Alternatives Grifols Alternatives TG Therapeutics Alternatives Lantheus Alternatives Nuvalent Alternatives Telix Pharmaceuticals Alternatives Axsome Therapeutics Alternatives ADMA Biologics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:HRMY) was last updated on 7/9/2025 by MarketBeat.com Staff From Our PartnersA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Harmony Biosciences Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Harmony Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
